

Santa Paula Hospital ED / Inpatient

SPH ED/IP ANTIBIOGRAM 2021 GRAM NEGATIVE % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amp/Sulbactam	Cefazolin*	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin*	Pip/Tazobactam	Tobramycin	Trimethoprim/Sulfa
<i>E. coli</i>	298	59	88	94	91	91	78	99	89	72	(99)	97	95	88	71
<i>Enterobacter cloacae</i>	16	0	0	100	N	N	100	94	100	94	(100)	38	94	100	94
<i>Klebsiella pneumoniae</i>	48	90	98	100	98	98	96	100	100	96	(100)	21	94	100	92
<i>Proteus mirabilis</i>	34	94	94	100	97	97	71	100	91	71	(100)	0	100	94	85
<i>Pseudomonas aeruginosa</i>	20	0	0	80	85	0	65	0	95	50	95	0	75	100	0

*Nitrofurantoin and cefazolin: use only for the treatment of uncomplicated cystitis

Cefazolin results predict results for oral cephalexin and cefuroxime when used to treat uncomplicated cystitis.

X: not tested

N: not recommended

(): presumed susceptibility

9% of *E. coli* are Extended Spectrum Beta Lactamase (ESBL) Producing

2% of *Klebsiella spp.* are ESBL producing

SPH ED/IP ANTIBIOGRAM 2021 GRAM POSITIVE % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amox/Clavulinate	Amp/Sulbactam	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Clindamycin	Erythromycin	Levofloxacin	Oxacillin	Penicillin	Tetracycline	Trimethoprim/Sulfa	Vancomycin
<i>Staphylococcus aureus</i>	62	N	N	X	(61)	X	X	N	79	58	N	61	0	94	87	100
<i>Enterococcus faecalis</i>	20	X	X	100	N	N	N	N	N	13	N	X	X	35	0	100

X: not tested

N: not recommended

(): presumed susceptibility

39% of *Staphylococcus aureus* are Methicillin Resistant (MRSA)

61% of *Staphylococcus aureus* are Methicillin Susceptible (MSSA)

Streptococcus pneumoniae: too few isolates to report

Data from isolate totals <30 may be statistically unreliable

VCMC/SPH Antimicrobial Stewardship Committee 3/3/2022